OVID
Ovid Therapeutics Inc.
There isn't enough reported data to score OVID yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
OVID Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
OVID's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
OVID PE Valuation
OVID has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
OVID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OVID's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
OVID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.16 | +$0.33 |
| Q2 2026 | -$0.23 | +$0.29 |
| Q1 2026 | -$0.21 | +$0.13 |
| Q4 2025 | -$0.23 | +$0.14 |
| Q3 2025 | -$0.49 | -$0.03 |
| Q2 2025 | -$0.52 | -$0.10 |
| Q1 2025 | -$0.34 | +$0.38 |
| Q4 2024 | -$0.37 | +$0.37 |
OVID is still losing money, but far less than before: $0.16 per share over the past year, against $1.46 at its worst in mid-2020.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over OVID on earnings quality, reporting a profit while its opponent remains loss making.
OVID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $733K | -88% |
| Q4 2025 | $718K | +845% |
| Q3 2025 | $132K | -24% |
| Q2 2025 | $6.3M | +3611% |
| Q1 2025 | $130K | -12% |
| Q4 2024 | $76K | -46% |
| Q3 2024 | $173K | +59% |
| Q2 2024 | $169K | +125% |
OVID's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2142% | -2061 points |
| Q4 2025 | -1712% | +12396 points |
| Q3 2025 | -9487% | -1842 points |
| Q2 2025 | -81% | +12059 points |
| Q1 2025 | -9654% | +2114 points |
| Q4 2024 | -14108% | -1260 points |
| Q3 2024 | -7645% | +3393 points |
| Q2 2024 | -12140% | +6756 points |
OVID's operating margin was −2142% last quarter, up 7512 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over OVID on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over OVID on profitability, with a higher operating margin.
OVID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.9M | -$3M |
| Q2 2026 | -$17.6M | -$12.8M |
| Q1 2026 | -$13.9M | -$3.6M |
| Q4 2025 | -$10.4M | -$378K |
| Q3 2025 | -$12.9M | +$2.1M |
| Q2 2025 | -$4.8M | +$9.5M |
| Q1 2025 | -$10.3M | +$6.4M |
| Q4 2024 | -$10M | +$1.9M |
OVID has burned cash in almost every quarter: −$58M over the past year, against −$38M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over OVID on cash generation, producing positive trailing cash flow while its opponent burns cash.
OVID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.4% | -6.6M shares |
| 1 year | +165% | +118M shares |
| 3 years | +167% | +118M shares |
| 5 years | +178% | +121M shares |
| Available history | +245% | +134M shares |
OVID has 189M diluted shares, up 165% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over OVID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
OVID Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -1.5x | Net Cash |
| Q3 2021 | -1.6x | Net Cash |
| Q2 2021 | -1.7x | Net Cash |
| Q1 2021 | -2.0x | Net Cash |
OVID has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
OVID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.0 | Neutral |
| Stochastic | 62.2 | Neutral |
OVID's weekly RSI is 52 (neutral) and its Stochastic is 62 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
OVID PE vs Healthcare Sector
OVID has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
OVID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.44 | 4.5% above |
| 20 week MA | $2.55 | 0% above |
| 50 week MA | $2.28 | 12% above |
| 100 week MA | $1.53 | 67% above |
| 200 week MA | $2.11 | 21% above |
OVID has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
OVID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.61 | $2.61 | -43% |
| 2021 | $2.61 | $3.39 | +30% |
| 2022 | $3.39 | $1.70 | -50% |
| 2023 | $1.70 | $3.22 | +89% |
| 2024 | $3.22 | $0.97 | -70% |
| 2025 | $0.97 | $1.78 | +84% |
| 2026 YTD | $1.78 | $2.55 | +43% |
OVID has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.